Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

In Partnership With:

Partner | Cancer Centers | <b>Rush University Cancer Center</b>

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

CDK4/6 inhibitors have had a dramatic impact on the management of patients with metastatic HR-positive, HER2- breast cancer. Currently, all 3 agents